AmpliPhi Biosciences’s proprietary phage technology and extensive library of phage products provides potential applications for a broad array of treatment needs. Initial studies have indicated that bacteriophages can work synergistically with traditional antibiotics, enabling products to be effective against otherwise resistant strains. In addition, phage treatments may prove effective for a variety of topical infections, including burns and wounds.
Latest News
March 27th 2012
“Using Viruses to Beat Superbugs,” AmpliPhi CSO Dr. David Harper featured in ScienceDaily
MoreMarch 08th 2012
“The Bacteriophage Comes of Age” in Medscape News
MoreJanuary 31st 2012
January 2012 Shareholder Letter
MoreJanuary 04th 2012
BioWorld Today features AmpliPhi CEO Phil Young
MoreNovember 21st 2011
AmpliPhi Biosciences Announces First Closing of $2.7m
More